

Doc code: IDS Approved for use through 07/31/2012. OMB 0854-0031

Doc description: Information Disclosure Statement (IDS) Filed U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it control number.

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	entee or Applicant iment	Pages,Columns,Lines when Relevant Passages or Relev Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Publica Code ¹ Date		tion Name of Patentee or Ap			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Publ	ished Ap			n information		d butto	on.	
				FOREIG	JN PAI	ENT DOCUM			Pages,Columns,Lines	Т
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		where Relevant Passages or Relevant Figures Appear	T5
	1	2000-0033008	KR			2000-06-15	Hyo Jeong Hong, e	et al.		×
	2	97/47654	wo			1997-12-18	Yair Reisner, et al.			×
	3	00/26394	wo							×

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10508759		
Filing Date		2004-09-22		
First Named Inventor Hyo		Jeong HONG		
Art Unit	-	1648		
Examiner Name	Agnie	eszka Boesen		
Attorney Docket Number		DE1586 (CONF. 9699)		

	4	1999-008650	KR		1999-02-05	Hyo Jeong Hong, et al.					
	5	1999-008649	KR		1999-02-05	Hyo Jeong Hong, et al.		×			
If you wish	to ac	dd additional Forei	n Patent Docume	nt citation	information p	lease click the Add butto	n				
			NON-PAT	ENT LITE	RATURE DO	CUMENTS					
Examiner Initials*	Cite No										
	1	TOMOYUKI NAKATANI et al., Humanization of mouse anti-human IL-2 receptor antibody B-B10; Protein Engineering Vol. 7 No. 3 pp. 435-443, 1994									
	2	S. STEPHENS et al., Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses; Immunology 85 pp. 668-674, 1995									
	3	IAN M. TOMLINSOIN, et al., The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops; J. Mol. Biol. 227, pp. 776-798, 1992									
	4	JEFFREY V. RAVETCH, et al., Structure of the human immunoglobulin u locus: characterization of embryonic and rearranged J and G genes; Cell, Vol. 27, pp. 583-591, Dec. 1981 (Part 2)									
	5	JONATHAN P.L. COX, et al., A directory of human germ-line VH segments reveals a strong bias in their usage; Eur. J. Immunol., 24, pp. 827-836, 1994									
	6	MAKOTO IWAHASHI, et al., CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity; Molecular Immunology, 36, pp. 1079-1091, 1999									

EDUARDO A. PADLAN, et al., Identification of specificity-determining residues in antibodies; The FASEB Journal, Vol. 9, pp. 133-139, January 1995

 \boxtimes

7

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10508759		
Filing Date		2004-09-22		
First Named Inventor Hyo J		eong HONG		
Art Unit		1648		
Examiner Name	Agnieszka Boesen			
Attorney Docket Number		DE1586 (CONF. 9699)		

8	CHUN JEIH RYU, et al., Cloning and sequence analysis of cDNAs encoding the heavy and light chain variable regions of a human monoclonal antibody with specificity for hepatitis 8 surface antigen; Biochimica et Biophysica Acta, 1380, pp. 151-155, 1998	×
9	CHUN JEIH RYU, et al., A humanized antibody with specificity for hepatitis B surface antigen; Hum. Antibod. Hybridomas, Vol. 7, 3, pp. 113-122, 1996	×
10	S.V.S. KASHMIRI, et al., Development of a minimally immunogenic variant of humanized anti-carcinoma monocional antibody CC49; Critical Reviews in Oncology/Hematology, 38, pp. 3-16, 2001	×
 11	STUART RUDIKOFF, et al., Single amino acid substitution altering antigen-binding specificity; Proc. Natl. Acad. Sci. USA, Vol. 79, pp. 1979-1983, March 1982, Immunology	×

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTD.GOV or MPEP 901.04.3 Enter office that Issued the document, by the two-letter code (WIPO Standard ST3.) For Japanese patent documents, by the indication of the year of the reign of the Emporor must precede the serial number of the patent document.

* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English Inaquese translation is attached.